Case Study: Geriatric Patient with Polypharmacy and Complex Needs

Patient Snapshot

Patient: Margaret Chen, 78-year-old female Chief Complaint: "My mouth is so dry, and my teeth are sensitive to cold, especially on the left side." ASA Classification: ASA III

Medical History

• Hypertension (diagnosed 20 years ago; reasonably controlled)
• Type 2 diabetes mellitus (diagnosed 12 years ago; HbA1c 7.2%)
• Atrial fibrillation (diagnosed 4 years ago)
• Osteoarthritis (knees and hands; diagnosed 10 years ago)
• Osteoporosis (diagnosed 7 years ago; T-score −2.6 at femoral neck)
• Chronic dry mouth for the past 3–4 years

Medications

• Apixaban (Eliquis) 5 mg BID — for atrial fibrillation (stroke prevention)
• Metformin 1,000 mg BID — for type 2 diabetes
• Lisinopril 20 mg daily — for hypertension
• Atorvastatin 20 mg daily — for hyperlipidemia
• Alendronate 70 mg weekly — for osteoporosis (taken for 5 years)
• Oxybutynin 5 mg BID — for overactive bladder (anticholinergic)
• Cetirizine 10 mg daily — for seasonal allergies (antihistamine)

Allergies

• Penicillin: Hives/rash (true allergy, not just intolerance)
• Adhesive bandage adhesive: Contact dermatitis (latex is NOT the issue; she tolerates latex gloves)

Vital Signs

• Blood pressure: 132/84 mmHg (right arm, seated)
• Heart rate: 72 bpm (irregularly irregular — consistent with atrial fibrillation)
• Respiratory rate: 16 breaths/min
• Temperature: 98.4°F (36.9°C)

Dental History

Mrs. Chen visits the dentist approximately every 12–18 months, though she has missed several appointments due to transportation challenges following her husband's death three years ago. She reports brushing once daily (morning) with a manual toothbrush and does not floss due to difficulty gripping floss ("my hands don't work like they used to"). She uses no mouth rinse. She sips water frequently throughout the day to manage dry mouth and consumes sugar-free lozenges. Last prophylaxis was 16 months ago. She has multiple existing restorations and wears no removable prostheses.

Periodontal Findings

Full-mouth probing reveals generalized probing depths of 3–5 mm with localized 6–7 mm pockets at teeth #14 (distal) and #19 (mesial). Clinical attachment loss ranges from 3–6 mm. Bleeding on probing is present at 32% of sites. Furcation involvement: Class I buccal furcation on #3 and #14; Class II buccal furcation on #19. No mobility. Localized recession of 2–3 mm on buccal surfaces of posterior teeth. Diagnosis: Stage III, Grade B periodontitis (generalized; moderate rate of progression).

Radiographic Findings

• Horizontal bone loss approximating 25–40% of root length in posterior sextants
• Vertical bone defect at distal of #14 approaching the furcation
• Root caries: Radiolucencies at the cervical margins of teeth #20 (mesial), #21 (facial), and #28 (distal)
• Coronal caries: Recurrent decay under existing amalgam on tooth #13 (distal)
• Multiple existing restorations: amalgams on #2, #3 (MOD), #14 (occlusal), #15, #18, #19 (MOD), #30, #31
• No periapical pathology

Clinical Findings

• Xerostomia: Pooling of saliva is minimal; oral mucosa appears dry; lips are cracked; tongue is fissured with minimal coating
• Root caries: Active root surface lesions on #20 (mesial), #21 (facial), #28 (distal) — soft, leathery consistency on explorer examination
• Coronal caries: Recurrent decay at distal margin of #13 amalgam
• Generalized attrition: Consistent with age; no signs of parafunction
• Oral hygiene: Fair; plaque accumulation at gingival margins, especially interproximal and on lingual surfaces of mandibular anteriors
• Mucosa otherwise within normal limits; no suspicious lesions

Risk Assessment

Caries risk: HIGH. Contributing factors:

• Xerostomia (medication-induced from oxybutynin + cetirizine; also age-related reduction in salivary flow)
• Existing root caries and recurrent decay
• Infrequent dental visits
• Inadequate plaque control
• High carbohydrate intake from sugar-free lozenges (low cariogenicity but still present in oral environment)

Periodontal risk: MODERATE. Contributing factors:

• Type 2 diabetes (HbA1c 7.2% = not optimally controlled)
• Inconsistent recare
• Inadequate interdental cleaning
• Existing attachment loss with furcation involvement

Bleeding risk: MODERATE. Apixaban (factor Xa inhibitor) increases bleeding tendency. However, for non-surgical periodontal therapy (scaling and root planing), the risk of significant bleeding is generally low. For surgical procedures, coordination with the prescribing physician regarding temporary interruption may be warranted.

MRONJ risk: LOW but present. Five-year history of oral bisphosphonate (alendronate). Risk of medication-related osteonecrosis of the jaw is low with oral bisphosphonates (<1% after dental extractions), but the risk is real and requires informed consent and atraumatic technique if extractions are needed.

Clinical Questions

Q1: Which TWO medications in Mrs. Chen's regimen are MOST likely contributing to her xerostomia?

Answer: Oxybutynin and cetirizine. Oxybutynin is an anticholinergic medication (used for overactive bladder) that directly inhibits salivary gland secretion via muscarinic receptor blockade. Cetirizine is a second-generation antihistamine with some anticholinergic activity. Together, these medications substantially reduce salivary flow. The NBDHE commonly tests anticholinergics, antihistamines, antidepressants (especially tricyclics and SSRIs), antihypertensives, and diuretics as causes of drug-induced xerostomia.

Q2: Mrs. Chen requires non-surgical periodontal therapy (scaling and root planing). What modifications to treatment are necessary given her apixaban use?

Answer: For non-surgical periodontal therapy (SRP), apixaban generally does NOT need to be interrupted. The American Dental Association and cardiology guidelines indicate that routine dental procedures including SRP can be performed safely without discontinuing direct oral anticoagulants (DOACs) like apixaban. The key modifications are: (1) Use local hemostatic measures (pressure, topical hemostatic agents, sutures if needed), (2) Treat smaller quadrants at a time rather than full-mouth debridement to limit bleeding surface area, (3) Avoid inferior alveolar nerve blocks or lingual infiltrations in the posterior mandible where bleeding into a confined space could compromise the airway — consider intraligamentary or infiltration anesthesia instead, (4) Confirm with the prescribing physician if surgical intervention is planned. The NBDHE tests the difference between procedures that require anticoagulant consultation (extractions, surgical procedures) vs. those that generally do not (SRP, prophylaxis).

Q3: What adaptive oral hygiene aids would you recommend for Mrs. Chen, given her osteoarthritis affecting hand dexterity?

Answer: (1) Power toothbrush with a large, ergonomic handle — reduces the manual dexterity required for effective plaque removal. (2) Floss holder or flossette — eliminates the need to wrap floss around fingers. (3) Interdental brushes with wide handles — easier to grip than floss for wider embrasure spaces that accompany recession. (4) Rubber tip stimulator or end-tuft brush — for accessing furcation areas. (5) Fluoride mouth rinse (0.05% NaF daily) — provides topical fluoride protection without requiring dexterity. (6) If grip is severely compromised, consider a toothbrush handle modification (bicycle grip, tennis ball, or universal cuff).

Q4: Mrs. Chen's root caries at teeth #20, #21, and #28 require restoration. What preventive measures should be implemented to manage her HIGH caries risk?

Answer: A multimodal caries prevention plan is necessary: (1) In-office 5% sodium fluoride varnish application at every recare visit (every 3–4 months rather than 6 months given HIGH risk). (2) Prescription-strength fluoride toothpaste (5,000 ppm NaF) for daily home use. (3) Xylitol products (mints, gum, lozenges) — 5–10 grams daily divided into 3–5 exposures to stimulate salivary flow and inhibit S. mutans. (4) Saliva substitutes containing fluoride and/or xylitol for symptomatic xerostomia relief. (5) Dietary counseling — reduce frequency of fermentable carbohydrate intake; encourage water as primary beverage. (6) Possible medication review with her primary care physician — could oxybutynin be switched to a non-anticholinergic alternative (e.g., mirabegron)? This addresses the ROOT CAUSE of her xerostomia. (7) Increased recare frequency to every 3–4 months for continued monitoring and fluoride application.

Q5: What considerations apply regarding Mrs. Chen's 5-year history of oral bisphosphonate use if tooth #14 (with the vertical bone defect and Class I furcation) ultimately requires extraction?

Answer: Oral bisphosphonate use for >3–4 years increases MRONJ risk, though the absolute risk remains low. Management: (1) Discuss with her prescribing physician — some protocols suggest a "drug holiday" (2–3 months off alendronate before extraction and until healing is complete), though the evidence for drug holidays preventing MRONJ is limited and controversial. (2) Informed consent — document that Mrs. Chen understands the MRONJ risk, however small. (3) Atraumatic extraction technique — minimize trauma to bone, smooth sharp edges, achieve primary closure if possible. (4) Chlorhexidine rinse pre- and post-operatively. (5) Close follow-up to monitor healing. (6) For SRP and nonsurgical care, no bisphosphonate-related modifications are required — MRONJ risk is triggered by procedures that expose bone.